| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Maryam Ravan, Duncan MacCrimmon, Gary Hasey, James P Reilly, Ahmad Khodayari-Rostamaba. A machine learning approach using P300 responses to investigate effect of clozapine therapy. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference. vol 2012. 2013-07-30. PMID:23367274. |
clozapine (clz) is uniquely effective as a treatment for medication resistant schizophrenia. |
2013-07-30 |
2023-08-12 |
human |
| Silvio Cacci. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatric drugs. vol 15. issue 3. 2013-07-30. PMID:23588704. |
recent controlled trials have demonstrated the efficacy of some of these agents (including aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) in adolescent schizophrenia and children or adolescent bipolar mania, or to treat severe aggression and self-injury in the context of autism in children and adolescents. |
2013-07-30 |
2023-08-12 |
Not clear |
| N Y Lee, M S Roh, S H Kim, D C Jung, H Y Yu, K H Sung, I W Chung, T Youn, U G Kang, Y M Ahn, Y S Ki. The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia. International clinical psychopharmacology. vol 28. issue 2. 2013-07-12. PMID:23211493. |
we reviewed the electromedical records of patients with schizophrenia who had taken clozapine as the sole antipsychotic for 3 months or more. |
2013-07-12 |
2023-08-12 |
Not clear |
| N Y Lee, M S Roh, S H Kim, D C Jung, H Y Yu, K H Sung, I W Chung, T Youn, U G Kang, Y M Ahn, Y S Ki. The prevalence of metabolic syndrome and its association with alanine aminotransferase in clozapine-treated Korean patients with schizophrenia. International clinical psychopharmacology. vol 28. issue 2. 2013-07-12. PMID:23211493. |
korean patients with schizophrenia who were receiving clozapine as the sole antipsychotic showed a high prevalence of mets. |
2013-07-12 |
2023-08-12 |
Not clear |
| Paul Glue, Christopher Gale, David B Menkes, Noelyn Hun. Evaluation of bioequivalence between clozapine suspension and tablet formulations : a multiple-dose, fed and fasted study. Clinical drug investigation. vol 32. issue 11. 2013-07-11. PMID:23018283. |
clozapine is the most effective drug for schizophrenia. |
2013-07-11 |
2023-08-12 |
Not clear |
| Oliver Freudenreich, David C Henderson, Kathy M Sanders, Donald C Gof. Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation. Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry. vol 37. issue 1. 2013-07-09. PMID:23338869. |
this matters because clozapine is an important evidence-based treatment for refractory schizophrenia that remains underutilized in clinical practice. |
2013-07-09 |
2023-08-12 |
Not clear |
| Joseph Martin Alisk. Cerebroventricular clozapine would be a viable treatment modality for clozapine-dependent schizophrenia patients with neutropenia. Medical hypotheses. vol 79. issue 4. 2013-07-08. PMID:22818272. |
cerebroventricular clozapine would be a viable treatment modality for clozapine-dependent schizophrenia patients with neutropenia. |
2013-07-08 |
2023-08-12 |
Not clear |
| Pradipta Majumder, R K Chadda, P Goyal, A Mittal, Nand Kuma. Clozapine induced eosinophilia. Indian journal of psychiatry. vol 53. issue 2. 2013-07-04. PMID:21772649. |
although there are reports of eosinophilia developing in course of treatment with clozapine among patients suffering from schizophrenia but this may be the first case of eosinophilia associated with clozapine use in case of schizoaffective disorder. |
2013-07-04 |
2023-08-12 |
Not clear |
| Alicia Hanes, Tammie Lee Demler, Claudia Lee, Alexander Campo. Pseudoephedrine for the treatment of clozapine-induced incontinence. Innovations in clinical neuroscience. vol 10. issue 4. 2013-07-04. PMID:23696957. |
clozapine, the first atypical antipsychotic, is well known for superior efficacy in the treatment of refractory schizophrenia. |
2013-07-04 |
2023-08-12 |
Not clear |
| Herbert Y Meltze. Update on typical and atypical antipsychotic drugs. Annual review of medicine. vol 64. 2013-07-02. PMID:23020880. |
clozapine is unique among the atypical apds in its efficacy for ameliorating psychosis in patients with treatment-resistant schizophrenia (trs), for reduction of suicide, and for improving longevity. |
2013-07-02 |
2023-08-12 |
Not clear |
| Handan Gunduz-Bruce, Stephen Oliver, Ralitza Gueorguieva, Kimberlee Forselius-Bielen, Deepak C D'Souza, Zoran Zimolo, Cenk Tek, Styliani Kaliora, Susan Ray, Georgios Petride. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophrenia research. vol 143. issue 2-3. 2013-07-02. PMID:23219861. |
efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. |
2013-07-02 |
2023-08-12 |
Not clear |
| Handan Gunduz-Bruce, Stephen Oliver, Ralitza Gueorguieva, Kimberlee Forselius-Bielen, Deepak C D'Souza, Zoran Zimolo, Cenk Tek, Styliani Kaliora, Susan Ray, Georgios Petride. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophrenia research. vol 143. issue 2-3. 2013-07-02. PMID:23219861. |
a substantial number of patients with treatment-resistant schizophrenia respond only partially to clozapine. |
2013-07-02 |
2023-08-12 |
Not clear |
| Handan Gunduz-Bruce, Stephen Oliver, Ralitza Gueorguieva, Kimberlee Forselius-Bielen, Deepak C D'Souza, Zoran Zimolo, Cenk Tek, Styliani Kaliora, Susan Ray, Georgios Petride. Efficacy of pimozide augmentation for clozapine partial responders with schizophrenia. Schizophrenia research. vol 143. issue 2-3. 2013-07-02. PMID:23219861. |
we have conducted a randomized double-blind placebo controlled clinical trial in patients with schizophrenia currently receiving clozapine with partial response, and tested the efficacy of pimozide augmentation on positive and negative symptoms and also on neurocognitive measures. |
2013-07-02 |
2023-08-12 |
Not clear |
| b' Sefa Vay\\xc4\\xb1so\\xc4\\x9flu, A Elif An\\xc4\\xb1l Ya\\xc4\\x9fc\\xc4\\xb1o\\xc4\\x9flu, S\\xc3\\xbcha Ya\\xc4\\x9fc\\xc4\\xb1o\\xc4\\x9flu, Sevilay Karahan, O\\xc4\\x9fuzhan Karc\\xc4\\xb1, S Can G\\xc3\\xbcrel, M K\\xc3\\xa2z\\xc4\\xb1m Yaz\\xc4\\xb1c\\xc4\\xb. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. Schizophrenia research. vol 143. issue 1. 2013-07-01. PMID:23217729.' |
lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. |
2013-07-01 |
2023-08-12 |
Not clear |
| b' Sefa Vay\\xc4\\xb1so\\xc4\\x9flu, A Elif An\\xc4\\xb1l Ya\\xc4\\x9fc\\xc4\\xb1o\\xc4\\x9flu, S\\xc3\\xbcha Ya\\xc4\\x9fc\\xc4\\xb1o\\xc4\\x9flu, Sevilay Karahan, O\\xc4\\x9fuzhan Karc\\xc4\\xb1, S Can G\\xc3\\xbcrel, M K\\xc3\\xa2z\\xc4\\xb1m Yaz\\xc4\\xb1c\\xc4\\xb. Lamotrigine augmentation in patients with schizophrenia who show partial response to clozapine treatment. Schizophrenia research. vol 143. issue 1. 2013-07-01. PMID:23217729.' |
several placebo controlled studies investigating lamotrigine augmentation of clozapine in schizophrenia patients with partial response have shown varying results. |
2013-07-01 |
2023-08-12 |
Not clear |
| Juliano S Souza, Monica Kayo, Ivson Tassell, Camila Bertini Martins, Helio Elki. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS spectrums. vol 18. issue 2. 2013-06-26. PMID:23253621. |
efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. |
2013-06-26 |
2023-08-12 |
Not clear |
| Juliano S Souza, Monica Kayo, Ivson Tassell, Camila Bertini Martins, Helio Elki. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS spectrums. vol 18. issue 2. 2013-06-26. PMID:23253621. |
clozapine is considered the gold standard for the treatment of patients with treatment-resistant schizophrenia (trs); however, randomized controlled trials (rct) of olanzapine showed efficacy similar to clozapine in patients with trs. |
2013-06-26 |
2023-08-12 |
Not clear |
| Ney C do Carmo Borges, Rafael B Astigarraga, Carlos E Sverdloff, Paulo R Galvinas, Bruno C Borges, Ronilson A Moren. Comparative bioavailability of two oral formulations of clozapine in steady state administered in schizophrenic volunteers under individualized dose regime. Current clinical pharmacology. vol 7. issue 4. 2013-06-18. PMID:22794154. |
this method agrees with the requirements proposed by the us food and drug administration of high sensitivity, specificity and high sample throughput and was used to evaluate the pharmacokinetic profiles and bioequivalence of the two clozapine formulations in twenty six schizophrenic patients affected by refractory schizophrenia under steady-state conditions. |
2013-06-18 |
2023-08-12 |
human |
| S Ozcan, A Soydan, L Tama. Supersensitivity psychosis in a case with clozapine tolerance. European review for medical and pharmacological sciences. vol 16 Suppl 4. 2013-06-12. PMID:23090814. |
despite its serious side effects, clozapine is still the golden standard in treatment of schizophrenia due to its effectiveness and lack of extrapyramidal side effects. |
2013-06-12 |
2023-08-12 |
Not clear |
| Feras Ali Mustaf. Schizophrenia past clozapine: what works? Journal of clinical psychopharmacology. vol 33. issue 1. 2013-06-12. PMID:23277242. |
schizophrenia past clozapine: what works? |
2013-06-12 |
2023-08-12 |
Not clear |